Document is current
Any future updates will be listed below
-
Authors
Goubet, Anne-Gaëlle http://orcid.org/0000-0003-3431-3067
Wheeler, Richard
Fluckiger, Aurélie
Qu, Bo
Lemaître, Fabien
Iribarren, Kristina
Mondragón, Laura
Tidjani Alou, Maryam
Pizzato, Eugénie
Durand, Sylvère
Derosa, Lisa
Aprahamian, Fanny
Bossut, Noélie
Moya-Nilges, Maryse
Derrien, Diane
Chen, Guo
Leduc, Marion
Joseph, Adrien
Pons, Nicolas
Le Chatelier, Emmanuelle
Segata, Nicola http://orcid.org/0000-0002-1583-5794
Yonekura, Satoru http://orcid.org/0000-0003-4047-3016
Iebba, Valerio
Kepp, Oliver http://orcid.org/0000-0002-6081-9558
Raoult, Didier
André, Fabrice
Kroemer, Guido
Boneca, Ivo Gomperts http://orcid.org/0000-0001-8122-509X
Zitvogel, Laurence http://orcid.org/0000-0003-1596-0998
Daillère, Romain
-
Funding
Funding for this research was provided by:
Fondation pour la Recherche Médicale
Ligue Contre le Cancer
Institut National Du Cancer
- License Information
-
More Information
Article History
Received: 3 September 2020
Revised: 8 February 2021
Accepted: 8 February 2021
First Online: 11 May 2021
Compliance with ethical standards
:
: RD, LZ, and GK are cofounders of EverImmune, a biotech company focused on the use of commensal bacteria for cancer treatment. FL and RD were employees of EverImmune.
: The institutional board of animal ethics and Ministère de la Recherche approved all mouse experimental settings (permission numbers: 2014-074-501, 2016-109-7450, 2018-013-13366, and 2019-076-23184). Stools from breast cancer patients were collected from CANTO study (NCT01993498). The study was approved by the Comité de Protection des Personnes IDF7 (Bicêtre, project: 11-039). All patients gave their consent for the use of their fecal material and the related data, to be published.
